Gemcitabine-Induced Hemolytic Uremic Syndrome in Pancreatic Cancer: A Case Report and Review of the Literature

• Published in: Gut and liver Vol. 8; no. 1; pp. 109 - 112
• Main Authors: Lee, Hye Won, Chung, Moon Jae, Kang, Huapyong, Choi, Heun, Choi, Youn Jeong, Lee, Kyung Joo, Lee, Seung Woo, Han†, Seung Hyuk, Kim, Jin Seok, Song, Si Young
• Format: Journal Article
• Language: English
• Published: Korea (South) The Korean Society of Gastroenterology; the Korean Society of Gastrointestinal Endoscopy; the Korean Association for the Study of the Liver; the Korean Society of Neurogastroenterology and Motility; Korean Association for the Study of Intestinal Diseases; Korean College of Helicobacter and Upper Gastrointestinal Research; Korean Pancreatobiliary Association; Korean Society of Gastrointestinal Cancer 01.01.2014; Gastroenterology Council for Gut and Liver; 거트앤리버 소화기연관학회협의회
• Subjects: Antimetabolites, Antineoplastic - adverse effects; Case Report; Deoxycytidine - adverse effects; Deoxycytidine - analogs & derivatives; gemcitabine; hemolytic-uremic syndrome; Hemolytic-Uremic Syndrome - chemically induced; Humans; Male; Middle Aged; pancreatic neoplasms; Pancreatic Neoplasms - drug therapy; Treatment Outcome; 내과학; Gemcitabine; Hemolytic-uremic syndrome; Pancreatic neoplasms
• ISSN: 1976-2283; 2005-1212; 2005-1212
• DOI: 10.5009/gnl.2014.8.1.109

Hemolytic uremic syndrome (HUS) is a rare thrombotic complication characterized by a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. HUS may be caused by several different conditions, including infection, malignancy, and chemotherapeutic agents, such as mitomycin, cisplatin, and most recently, gemcitabine. The outcome of gemcitabine-induced HUS is poor, and the disease has a high mortality rate. This study reports a case of gemcitabine-induced HUS in a patient with pancreatic cancer in Korea.